GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Nicolaus Kröger, Carlos Solano et al.|The Lancet Haematology|2019Cited by 58
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemiaEsther Onecha, Rosa Ayala, Eduardo Anguita et al.|Haematologica|2018Cited by 51
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Bruno Paiva et al.|Blood Advances|2021Cited by 25
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>ex vivo</i> chemosensitivityEsther Onecha, Rosa Ayala, Yanira Ruiz‐Heredia et al.|British Journal of Haematology|2020Cited by 14
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha et al.|Cancers|2021Cited by 12